Clinical Trials Logo
  1. Home
  2. Pediatric Brain Tumor
  3. NCT03068832

Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors

Pediatric Brain Tumor Clinical Trial

Official title:
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors

Clinical Trial Summary

The early clinical development paradigm for chemotherapeutic agents has significantly influenced the development of therapeutic cancer vaccines. However, there are major differences between these two classes of therapeutics that have important implications for early clinical development. Specifically, the phase 1 concept of dose escalation to find a maximum-tolerated dose does not apply to most therapeutic cancer vaccines. Most therapeutic cancer vaccines are associated with minimal toxicity at a range that is feasible to manufacture or administer, and there is little reason to believe that the maximum-tolerated dose is the most effective dose. In a recent article from the biostatistics literature, Simon et al. write that "the initial clinical trial of many new vaccines will not be a toxicity or dose-ranging trial but rather will involve administration of a fixed dose of vaccine … in most cases the dose selected will be based on preclinical findings or practical considerations. Using several dose levels in the initial study to find the minimal active dose or to characterize the dose-activity relationship is generally not realistic". Consistent with these recommendations, the general philosophy of the phase 1 clinical trial is to facilitate a prompt preliminary evaluation of the safety and immunogenicity of the personalized synthetic long peptide vaccine strategy. The proposed clinical trial will test a fixed dose of vaccine. There is considerable experience with the synthetic long peptide vaccine platform. The synthetic long peptide vaccine platform has an excellent safety profile, and the optimal dose appears to be based on practical considerations (solubility of the peptide). The dose to be tested in the proposed clinical trial is consistent with other similar cancer vaccine trials that have been recently completed or are currently ongoing. The sample size (n=10-20) will provide a reasonably reliable estimate of the safety and immunogenicity of the vaccine.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03068832
Study type Interventional
Source Washington University School of Medicine
Contact
Status Withdrawn
Phase Phase 1
Start date September 30, 2021
Completion date February 28, 2026
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03330197 - A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG Phase 1/Phase 2
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Recruiting NCT05367076 - Fitness to Aid the Brain and Cognitive Skills N/A
Completed NCT03615404 - Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma Phase 1
Completed NCT04351035 - National Wide Cross-sectional Study in Paediatric Central Nervous System Tumours in China -- the CNOG-MC001 Registry
Completed NCT01707836 - Neurofibromatosis Type 1 Brain Tumor Genetic Risk N/A
Withdrawn NCT03577600 - Compassionate Treatment in Children With Brain Tumors With the Cytotron® N/A
Completed NCT04659421 - Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas Phase 2
Active, not recruiting NCT03739372 - Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma N/A
Suspended NCT03334162 - Playful Sensorimotor Training in Pediatric Brain Tumor Patients N/A
Withdrawn NCT01861990 - Valproic Acid in Childhood Progressive Brain Tumors Phase 1
Recruiting NCT06226519 - Integrated PET/MRI and Germline Variants to Differentiate Brain Tumopr Recurrence From Iatrogenicchanges in Children
Terminated NCT03591861 - Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis N/A
Completed NCT04944875 - Effects of Music and Maternal Voice on Sedation Depth and Sedative Use During Pediatric Magnetic Resonance Imaging. N/A
Active, not recruiting NCT03434262 - SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Phase 1
Active, not recruiting NCT04239092 - 9-ING-41 in Pediatric Patients With Refractory Malignancies. Phase 1
Active, not recruiting NCT03208387 - Understanding the Late Effects of Surviving a Pediatric Brain Tumor
Recruiting NCT05528939 - Feasibility/Acceptability of Attentional-Control Training in Survivors N/A
Not yet recruiting NCT05887882 - Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Brain Tumors Phase 1
Recruiting NCT05740839 - High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study N/A